Drugs News and Research

RSS

Lotus Pharmaceuticals reports EBIT increase of 29% in 2009

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") reported that its 2009 net earnings were approximately $16.4 million, or $0.33 per diluted share, compared with approximately $12.8 million, or $0.27 per diluted share, in 2008. Net revenues were approximately $57.8 million in 2009 compared with $73.8 million in 2008.

1 Apr 2010

Catalyst Pharmaceutical Partners reports net loss of $7.24M for fourth-quarter 2009

Catalyst Pharmaceutical Partners, Inc., a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of diseases of the central nervous system, today reported financial results for the fourth quarter and year ended December 31, 2009.

1 Apr 2010

PolyMedix secures $14M credit facility with Hercules Technology II

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has secured a $14 million credit facility with Hercules Technology II, L.P., an affiliate of Hercules Technology Growth Capital, Inc.

1 Apr 2010

Investment report on ADVENTRX Pharmaceuticals

BeaconEquity.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

1 Apr 2010

Ensuring medication compliance in clinical trials: Pill capsules with microchips to signal ingestion

Seeking a way to confirm that patients have taken their medication, University of Florida engineering researchers have added a tiny microchip and digestible antenna to a standard pill capsule. The prototype is intended to pave the way for mass-produced pills that, when ingested, automatically alert doctors, loved ones or scientists working with patients in clinical drug trials.

1 Apr 2010

First Edition: April 1, 2010

According to today's headlines, President Obama will head to Maine to continue efforts to sell the new health reform law. Meanwhile, his administration is ramping up education plans and efforts to smooth the shift.

1 Apr 2010

Health care law: Planned, well-financed lobbying strategy leads to impressive list of wins for U.S. drug industry

Emerging Healthcare Solutions, Inc.. The U.S. drug industry fended off price curbs and other hefty restrictions in The President's health care law even as it prepares for plenty of new business when an estimated 32 million uninsured Americans gain health coverage. Lobbyists beat back proposals to allow importation of low-cost medicines and to have Medicare negotiate drug prices with companies.

1 Apr 2010

Data of focusing on Rebif and Cladribine Tablets to be presented at AAN Annual Meeting

EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced that new data from the company's multiple sclerosis portfolio of approved and investigational treatments will be presented at the 62nd Annual Meeting of the American Academy of Neurology taking place April 10 to 17, in Toronto, Canada.

1 Apr 2010

Pramipexole ER uptake to be inhibited by availability of generic version

HealthLeaders-InterStudy and Fingertip Formulary find that the uptake of Boehringer Ingelheim's pramipexole ER, the once-daily formulation of its market leading dopamine agonist Mirapex that was approved earlier this month, will be inhibited by competition from generic pramipexole which became available earlier this year.

1 Apr 2010

Mtb fine-tunes behaviour to escape detection and causes TB

Mycobacterium tuberculosis (Mtb) possesses extraordinary survival ability by masking itself from the host immune system and persisting for decades inside the host. Speaking at the Society for General Microbiology's spring meeting in Edinburgh today, Dr Kristine Arnvig provides further insight into how the bacterium causes tuberculosis (TB) by fine-tuning its behaviour in response to its surroundings to escape detection.

1 Apr 2010

Pfizer admits paying $35 million to doctors over last 6 months

Pfizer among other large pharmaceutical companies recently disclosed payments to doctors and other medical professionals for consulting and speaking on its behalf and also some sponsorship of clinical trials. On Wednesday in an announcement the company spokesperson revealed that they had paid a whopping $20 million to 4,500 doctors and other medical professionals in the last six months of 2009. Pfizer also accepted that they paid $15.3 million to 250 academic medical centers and other research groups for clinical trials in the same period. This disclosure is only about payments made within the US.

1 Apr 2010

Neurologist develops SAGE tool to diagnose memory disorders

A self-administered test to screen for early dementia could help speed the diagnosis and subsequent treatment of memory disorders, including Alzheimer's disease. It could also provide health care providers and caregivers an earlier indication of life-changing events that could lie ahead.

1 Apr 2010

New health care reform law includes patient safety provisions

While most of the attention surrounding the landmark health care reform measure just signed into law has focused on how it expands access to affordable insurance coverage, it also enacts important initiatives that will improve patient safety, according to Consumers Union, the nonprofit publisher of Consumer Reports.

1 Apr 2010

Counterfeit pharmaceutical products: Practicable and entirely detectable identification with RFID

A detailed product proof and improved security against counterfeiting pharmaceutical products become more and more important, especially nowadays when customers can order their drugs online. The legislative pressure increases primarily for reasons of patient safety, incorrect medications, and drug counterfeiting.

1 Apr 2010

Major breakthrough may help develop low toxicity drugs for sleeping sickness

Scientists from the Drug Discovery Unit at the University of Dundee - working together with partners at the University of York and the Structural Genomics Consortium in Toronto - have made a major breakthrough in identifying new treatments for a fatal disease which infects tens of thousands of Africans each year.

1 Apr 2010

TCA may be an effective treatment option for patients who suffer from PVOD

Traditional Chinese acupuncture, where very thin needles are used to stimulate specific points in the body to elicit beneficial therapeutic responses, may be an effective treatment option for patients who suffer from persistent post- viral olfactory dysfunction, according to new research in the April 2010 issue of Otolaryngology - Head and Neck Surgery.

1 Apr 2010

Cell study may yield new treatment strategies for debilitating diseases

A Los Alamos National Laboratory toxicologist and a multidisciplinary team of researchers have documented potential cellular damage from "fullerenes"-soccer-ball-shaped, cage-like molecules composed of 60 carbon atoms. The team also noted that this particular type of damage might hold hope for treatment of Parkinson's disease, Alzheimer's disease, or even cancer.

1 Apr 2010

States face health care budget cuts, seek health-related legislation

Parents, caregivers and advocates joined hospital executives and legislators Tuesday to complain about the potential impact of [Louisiana] Gov. Bobby Jindal's proposed budget cuts and privatization initiatives on Louisiana's most vulnerable residents.

1 Apr 2010

Crack, cocaine usage increases risk of HIV in adolescents

Teens with a history of crack or cocaine use are significantly more likely to engage in unprotected sex than youth who have never used these drugs, putting themselves at increased risk for HIV, according to a study in the April issue of the Journal of Child and Adolescent Substance Abuse.

1 Apr 2010

Dutasteride reduces risk of prostate cancer

There is good news for those at high risk for prostate cancer. The drug dutasteride which is manufactured by GlaxoSmithKline as the drug Avodart, has been found to reduce the risk of prostate cancer by a quarter. The drug is at present being used to treat enlarged prostates.

1 Apr 2010